Cognition Therapeutics Inc CGTX

Healthcare

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.

NDAQ:CGTX - Post by User

Cognition Therapeutics Inc

Bullboard Posts

Next >>

Post by ubiquitousmanon May 20, 2023 1:40pm

112 Views

Post# 35457848

Ok, I will start, stock closed at $2.17 5-19-23-could be ..

interesting. Different take on AD. High risk play but I could make a case for this to
be a $50-$100 stock in 24 months if they can prove efficacy in AD treatment. Stay
tuned. Minute market cap of $60MM, plenty of cash for year or two. Totally ignored
stock.

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 8, 2024)